Investigation of molecular signature involved in therapy-resistant small cell lung cancer based on understanding of functional RNA sequencing data integration.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K17640
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Kagoshima University
• Principal Investigator: Misono Shunsuke 鹿児島大学, 鹿児島大学病院, 医員 (30837779)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 小細胞肺癌 / 機能性RNA

Outline of Final Research Achievements

Small cell lung cancer (SCLC) has an extremely poor prognosis. Elucidating the molecular mechanisms that cause treatment resistance, recurrence, and distant metastasis may lead to the development of therapy. In this study, the molecular signature of SCLC specimens after treatment failure was generated using next generation sequencing (NGS) and microarray. In this profiles, Aberrant expression of MCM2, MCM4, MCM6, and MCM7 were detected in SCLC clinical specimens after treatment failure. Functional analysis revealed that these genes are oncogenes and alter sensitivity to anticancer drugs (cisplatin).

Free Research Field

呼吸器内科学

Academic Significance and Societal Importance of the Research Achievements

化学療法後に治療抵抗性を獲得した小細胞肺癌に対する治療は限定的である。小細胞肺癌に対して有効性が示された分子標的薬は未だ存在しない。本研究では、治療抵抗性となった小細胞肺癌の3例の剖検検体から機能性RNA発現プロファイルを作成し、癌の進行に関連する遺伝子を特定した。同様の研究を継続していくことにより、治療抵抗性となった小細胞肺癌に対する新規治療法の開発へ向けて重要な知見を提供する。